Keller CW, Chuquisana O, Derdelinckx J, Gross CC, Berger K, Robinson J, Nimmerjahn F, Wiendl H, Willcox N, Lünemann JD (2022)
Publication Type: Journal article
Publication year: 2022
DOI: 10.1002/ana.26507
Myasthenia gravis (MG) is an autoimmune disease in which pathogenic immunoglobulin G antibodies bind to acetylcholine receptors (or to functionally related molecules at the neuromuscular junction). B cell expression of the inhibitory immunoglobulin G receptor, Fc-gamma receptor (FcγR) IIB, maintains peripheral immune tolerance, and its absence renders B cells hyperresponsive to autoantigen. Here, we report that FcγRIIB expression levels are substantially reduced in B lineage cells derived from immunotherapy-naïve patients with acetylcholine receptor antibody-positive early-onset MG. In contrast, genetic variants associated with impaired FcγRIIB expression are not enriched in MG, indicating post-transcriptional dysregulation. FcγR-targeted therapies could have therapeutic benefits in MG. ANN NEUROL 2022.
APA:
Keller, C.W., Chuquisana, O., Derdelinckx, J., Gross, C.C., Berger, K., Robinson, J.,... Lünemann, J.D. (2022). Impaired B Cell Expression of the Inhibitory Fcγ Receptor IIB in Myasthenia Gravis. Annals of Neurology. https://doi.org/10.1002/ana.26507
MLA:
Keller, Christian W., et al. "Impaired B Cell Expression of the Inhibitory Fcγ Receptor IIB in Myasthenia Gravis." Annals of Neurology (2022).
BibTeX: Download